The impact of the genome-wide supported variant in the cyclin M2 gene on gray matter morphology in schizophrenia

Table 1 Genotype and allele distributions for each SNP between the patients with schizophrenia and healthy subjects

SNP IDs	Gene	Chr	Risk	Genotype frequencies						Risk allele		Allelic	OR
SNP IDs	Gene	Chr	allele	+/+	+/-	-/-	+/+	+/-	-/-	frequencies		p value	(95% CI)
			+/-	SCZ (n = 173)			CON (n = 449)			SCZ	CON	(χ2)	(95% CI)
rs10503253	CSMD1	8p23.2	A/C	0.06	0.46	0.49	0.09	0.46	0.45	0.29	0.32	0.22 (1.5)	1.19 (0.90-1.56)
rs7004633	MMP16	8q21.3	G/A	0.03	0.37	0.60	0.06	0.36	0.57	0.21	0.25	0.24 (1.4)	1.20 (0.89-1.61)
rs7914558	CNNM2	10q24.32	G/A	0.23	0.53	0.24	0.29	0.49	0.22	0.49	0.53	0.23 (1.4)	1.16 (0.91-1.49)
rs11191580	NT5C2	10q24.33	T/C	0.49	0.42	0.09	0.50	0.42	0.07	0.70	0.72	0.55 (0.4)	1.09 (0.83-1.43)
rs12966547	CCDC68	18q21	G/A	0.15	0.44	0.41	0.17	0.44	0.39	0.37	0.39	0.54 (0.4)	1.09 (0.84-1.41)

Abbreviations: Chr Chromosome; SCZ patients with schizophrenia; CON healthy controls; +, risk allele; -, non-risk allele; OR odds ratio.
For alleles, the first allele is the risk allele. All risk alleles are represented based on the previous GWAS [7].